Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: A noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1918-1934

  Pfútzner, Andreas ^a   Hartmann, Klaus ^b   Winter, Franziska ^c   Fuchs, Gitte SchOning ^d   Kappelgaard, Anne Marie ^d,e   Rohrer, Tilman R ^f  

^a IKFE Institute for Clinical Research and Development   (Germany)

^b Institute of Pediatric Endocrinology   (Germany)

^c IKFE GmbH   (Germany)

^d NOVO NORDISK A S   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

Disposable; Dose accuracy; Growth hormone; Injection device; Intuitiveness; Patient preference

Indexed keywords

HUMAN GROWTH HORMONE;

ACCURACY; ADOLESCENT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOSE CALCULATION; DRUG DELIVERY SYSTEM; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SMALL FOR DATE INFANT; TURNER SYNDROME;

ADOLESCENT; CHILD; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; INJECTIONS; MALE; MEDICATION ERRORS; REPRODUCIBILITY OF RESULTS; SELF ADMINISTRATION; TIME FACTORS; TURNER SYNDROME;

EID: 78649339291     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.010     Document Type: Article

References (35)

1. Massa G, Otten BJ, de Muinck Keizer-Schrama SM, et al. Treatment with two growth hormone regimens in girls with Turner syndrome: Final height results. Horm Res. 1995, 43:144-146. Dutch Growth Hormone Working Group.
2. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: Results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999, 84:4607-4612.
3. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003, 88:1119-1125.
4. Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after longterm, continuous growth hormone (GH) treatment in short children born small for gestational age: Results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab. 2003, 88:3584-3590.
5. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000, 85:3990-3993. Growth Hormone Research Society.
6. Ho KK Consensus guidelines for the diag- nosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007, 157:695-700. 2007 GH Deficiency Consensus Workshop Participants.
7. Piette JD, Heisler M, Krein S, Kerr EA The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. 2005, 165:1749-1755.
8. Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical prac- tice. Clin Ther. 2008, 30:307-316.
9. Blethen SL, Baptista J, Kuntze J, et al. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab. 1997, 82:418-420. Genentech Growth Study Group.
10. Rappaport R, Mugnier E, Limoni C, et al. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. J Clin Endocrinol Metab. 1997, 82:452-456. French Serono Study Group.
11. Bannink E, van Doorn J, Mulder PG, Hokken-Koelaga AC Free/dissociable insulin-like growth factor (IGF)-I, not total IGF-I, correlates with growth response during growth hormone treatment in children born small for gestational age. J Clin Endocrinol Metab. 2007, 92:2992-3000.
12. Desrosiers P, O'Brien F, Blethen S Patient outcomes in the GHMoni- tor: The effect of delivery device on compliance and growth. Pediatr Endocrinol Rev. 2005, 2(Suppl 3):327-331.
13. Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008, 93:147-148.
14. Lanes R Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol. 2004, 3:53-66.
15. Schifferdecker E, Schmidt K, Boehm BO, Schatz H Long-term compliance of intensified insulin therapy. Diabetes Res Clin Pract. 1994, 23:17-23.
16. Chan H Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. J AdvNurs. 2001, 35:882-892.
17. Bellary S, Barnett AH Inhaled insulin (Exubera): Combining efficacy and convenience. Diab Vasc Dis Res. 2006, 3:179-185.
18. Korytkowski M, Niskanen L, Asakura T FlexPen: Addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005, 27(Suppl B):S89-S100.
19. Smith SL, Hindmarsh PC, Brook CG Compliance with growth hor- mone treatment-are they getting it?. Arch Dis Child. 1993, 68:91-93.
20. Fidotti E A history of growth hormone injection devices. J Pediatr Endocrinol Metab. 2001, 14:497-501.
21. Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 2006, 6:5.
22. Ida S, Yoshimura N, Nakacho M, et al. Evaluation of the use of Pen-Needle 32G taper in children being treated with growth hormone. Clin Pediatr Endocrinol. 2008, 17:1-7.
23. Arendt-Nielsen L, Egekvist H, Bjerring P Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006, 23:37-43.
24. Oyarzabal M, Aliaga M, Chueca M, et al. Multicentre survey on compliance with growth hormone therapy: What can be improved?. Acta Paediatr. 1998, 87:387-391.
25. Korytkowski M When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002, 26(Suppl 3):S18-S24.
26. World Medical Association Decla-ration of Helsinki, Accessed May 25, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
27. Senn S Cross-Over Trials in Clinical Research 2002, John Wiley & Sons, Hoboken, NJ. 2nd ed.
28. Package insert for Norditropin Flex-Pro 2010, Novo Nordisk A/S, Bagsvήrd, Denmark. http://www.norditropinhcp.com/Content/pdf/norditropin-pi.pdf.
29. Package insert for easypod 2007, Merck Serono SA, Geneva, Switzerland. http://www.saizenus.com/pdfs/easypod_IFU_complete.pdf.
30. Package insert for Genotropin 2007, Pfizer Inc, New York, New York. http://www.pfizer.com/files/products/uspi_genotropin.pdf.
31. Reimer T, Hohberg C, Pfútzner AH, et al. Intuitiveness, instruction time, and patient acceptance of a pre- filled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008, 30:2252-2262.
32. Tauber M, Payen C, Cartault A, et al. User trial of Easypod, an electronic autoinjector for growth hor-mone. Ann Endocrinol (Paris). 2008, 69:511-516.
33. Ahmed SF, Smith WA, Blamires C Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis. Arch Dis Child. 2008, 93:110-114.
34. Wickramasuriya BP, Casey A, Akhtar S, et al. Factors determining patient choice of device for GH therapy. Horm Res. 2006, 65:18-22.
35. Dahlgren J Easypod: A new electronic injection device for growth hormone. Exp Rev Med Devices. 2008, 5:297-304.